Profile data is unavailable for this security.
About the company
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
- Revenue in USD (TTM)26.98m
- Net income in USD-180.66m
- Incorporated2017
- Employees284.00
- LocationBicycle Therapeutics PLCBabraham HallCAMBRIDGE CB21 6GSUnited KingdomGBR
- Phone+44 122 326 1503
- Websitehttps://www.bicycletherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
USANA Health Sciences, Inc. | 921.01m | 63.79m | 836.39m | 1.80k | 13.18 | 1.67 | 10.93 | 0.9081 | 3.30 | 3.30 | 47.61 | 25.99 | 1.50 | 2.75 | -- | 511,672.20 | 10.38 | 16.23 | 13.20 | 21.75 | 80.82 | 81.42 | 6.93 | 8.96 | 3.00 | -- | 0.0016 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
Nurix Therapeutics Inc | 80.89m | -144.73m | 856.34m | 284.00 | -- | 4.20 | -- | 10.59 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
OPKO Health Inc | 863.49m | -188.86m | 857.30m | 3.93k | -- | 0.6847 | -- | 0.9928 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
Ocular Therapeutix Inc | 58.44m | -80.74m | 870.96m | 267.00 | -- | 7.39 | -- | 14.90 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
Eyepoint Pharmaceuticals Inc | 46.02m | -70.80m | 872.04m | 121.00 | -- | 3.22 | -- | 18.95 | -1.84 | -1.84 | 1.18 | 5.43 | 0.1719 | 1.36 | 5.64 | 380,314.10 | -26.44 | -40.44 | -32.35 | -47.79 | 89.93 | 83.45 | -153.84 | -186.23 | 5.39 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
Zentalis Pharmaceuticals Inc | 0.00 | -292.19m | 889.84m | 168.00 | -- | 2.03 | -- | -- | -4.56 | -4.56 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -50.65 | -47.40 | -57.28 | -54.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
Cassava Sciences Inc | 0.00 | -97.22m | 916.38m | 29.00 | -- | 6.51 | -- | -- | -2.32 | -2.32 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -50.31 | -30.74 | -53.23 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
BioCryst Pharmaceuticals Inc | 331.41m | -226.54m | 927.67m | 536.00 | -- | -- | -- | 2.80 | -1.18 | -1.18 | 1.72 | -2.21 | 0.6212 | 0.1658 | 6.16 | 618,306.00 | -42.46 | -47.95 | -55.84 | -64.89 | 98.59 | 97.06 | -68.36 | -114.94 | 3.12 | -1.11 | 2.19 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
Innoviva Inc | 310.46m | 179.72m | 928.81m | 112.00 | 6.55 | 1.38 | 4.31 | 2.99 | 2.24 | 2.24 | 3.96 | 10.66 | 0.2509 | 0.8825 | 4.19 | 2,771,991.00 | 14.52 | 26.24 | 15.62 | 28.53 | 86.27 | -- | 57.89 | 76.84 | 7.96 | -- | 0.398 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
Bicycle Therapeutics PLC (ADR) | 26.98m | -180.66m | 929.82m | 284.00 | -- | 2.80 | -- | 34.47 | -5.13 | -5.13 | 0.7585 | 8.74 | 0.0536 | -- | 26.38 | 94,985.91 | -35.92 | -29.45 | -40.92 | -32.98 | -- | -- | -669.72 | -571.36 | -- | -- | 0.0764 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Viridian Therapeutics Inc | 314.00k | -237.73m | 951.56m | 96.00 | -- | 3.48 | -- | 3,030.43 | -5.32 | -5.32 | 0.007 | 8.19 | 0.0007 | -- | 3.08 | 3,340.43 | -51.37 | -55.59 | -54.93 | -60.32 | -- | -- | -75,711.47 | -5,678.12 | -- | -- | 0.0437 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
Pharvaris NV | 0.00 | -107.36m | 991.30m | 82.00 | -- | 2.36 | -- | -- | -2.69 | -2.69 | 0.00 | 7.82 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
Petro Usa Inc | 0.00 | -33.38k | 1.00bn | -- | -- | -- | -- | -- | -0.0002 | -0.0002 | 0.00 | -0.0008 | 0.00 | -- | -- | -- | -19,074.29 | -192,120.00 | -- | -- | -- | -- | -- | -- | -- | -118.21 | -- | -- | -- | -- | -81.58 | -- | -- | -- |
MacroGenics Inc | 58.75m | -9.06m | 1.01bn | 339.00 | -- | 6.54 | 1,715.61 | 17.11 | -0.1525 | -0.1525 | 0.9462 | 2.46 | 0.203 | 6.15 | 1.76 | 173,300.90 | -3.13 | -37.76 | -3.82 | -45.53 | 86.00 | -- | -15.42 | -133.96 | 4.46 | -117.57 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
SS Innovations International Inc | 5.88m | -20.94m | 1.02bn | 239.00 | -- | 71.04 | -- | 172.77 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Silence Therapeutics plc | 34.87m | -53.00m | 1.02bn | 116.00 | -- | 37.32 | -- | 29.37 | -0.487 | -0.487 | 0.3197 | 0.2144 | 0.2527 | -- | 94.73 | 300,595.30 | -38.40 | -43.18 | -47.88 | -53.35 | 54.24 | -- | -151.98 | -422.12 | -- | -15.11 | 0.0155 | -- | 40.97 | 305.31 | -2.74 | -- | 149.02 | -- |
Holder | Shares | % Held |
---|---|---|
Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 3.71m | 9.79% |
Deep Track Capital LPas of 31 Dec 2023 | 3.49m | 9.22% |
Baker Bros. Advisors LPas of 31 Jan 2024 | 2.05m | 5.41% |
Jefferies LLCas of 31 Dec 2023 | 1.95m | 5.14% |
Tybourne Capital Management (HK) Ltd.as of 31 Dec 2023 | 1.65m | 4.36% |
First Light Asset Management LLCas of 31 Dec 2023 | 1.55m | 4.09% |
Armistice Capital LLCas of 31 Dec 2023 | 1.54m | 4.06% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.03m | 2.71% |
Polar Capital LLPas of 31 Dec 2023 | 1.00m | 2.65% |
Westfield Capital Management Co. LPas of 31 Dec 2023 | 917.30k | 2.42% |